실적분석 2026년 8월 5일

Novo Nordisk ($NVO) Q2 2026 Earnings Analysis — Adjusted Results and Guidance Raised, Modest After-Hours Rebound

Earnings Scorecard

Revenue: DKK 78.488 billion (+2% YoY, +3% at constant exchange rates, vs. expected DKK 71.393 billion) ✅ Beat

EPS: Adjusted diluted DKK 6.18 (+5% YoY, vs. expected $4.98) ✅ Beat · IFRS diluted DKK 4.75 (-20% YoY)

Guidance: Raised — 2026 adjusted revenue growth 0% to -6% (constant exchange rates), adjusted operating profit growth 0% to -6% (raised from prior -4% to -12%)

Stock Reaction: After-hours +0.56% ($44.53) — as of 20:45 KST on Aug 5

Positives

Strong Adjusted Results: Q2 adjusted revenue DKK 78.488 billion (+7% at constant exchange rates), adjusted operating profit DKK 33.389 billion (+11%)

Guidance Upgrade: Full-year adjusted revenue and operating profit outlook raised to 0% to -6%, an improvement from the prior -4% to -12%

Wegovy Oral Spread: Cumulative US prescriptions surpassed 5 million, with weekly prescriptions exceeding 265,000 (week of July 17)

Novo Nordisk is a global pharmaceutical company focused on obesity and diabetes treatments. In Q2 2026, on an adjusted basis that strips out one-off items, both revenue and operating profit exceeded the prior-year period. The company said increased volume from its GLP-1 portfolio and the effect of US rebate adjustments drove the adjusted results.

The full-year outlook was also lifted one notch. The company raised its May guidance of -4% to -12% (at constant exchange rates) for adjusted revenue and adjusted operating profit growth to 0% to -6%, citing higher sales expectations for GLP-1 products as the rationale. Wegovy oral has surpassed 5 million cumulative prescriptions since its US launch, and early feedback from launches in the UAE and the UK has been encouraging, according to the company. In Europe, Wegovy high-dose (7.2mg) pen and oral formulations received approval from the European Medicines Agency, laying the groundwork for second-half launches.

Negatives

Decline in IFRS Profit: Q2 net profit DKK 20.989 billion (-21% YoY), diluted EPS DKK 4.75 (-20%)

Pipeline Impairment: Non-cash impairment charge of DKK 6.3 billion (including DKK 4.0 billion for monlunabant) pressured reported operating profit

Full-Year Growth Range Still in Negative Territory: Even after the upgrade, the adjusted revenue and operating profit growth guidance of 0% to -6% leaves room for a potential contraction

On a reported basis, the picture is less rosy. Q2 2026 operating profit came in at DKK 27.061 billion, down 16% at constant exchange rates, while net profit fell 21%. A reversal of rebate provisions related to the US Section 340B drug pricing program (DKK 2.6 billion) in the prior-year quarter created a tougher base effect, and a DKK 6.3 billion non-cash impairment of intangible pipeline assets this quarter (including DKK 4.0 billion for monlunabant) shaved operating profit.

The cardiovascular candidate ziltivekimab failed to meet the primary endpoint in the ZEUS Phase 3 trial. Even with the raised annual guidance, the top end of the range sits at 0% and the bottom end remains negative, suggesting this is closer to a "narrowing of declines" than a "return to growth." The question of how much of the volume growth will flow through to profit amid price cuts and intensifying competition remains under scrutiny.

What Management Said

Management's tone leans toward execution confidence rather than defense. President and CEO Mike Doustdar pointed to the Wegovy franchise as the core driver of 2026 growth, explaining that the spread of Wegovy oral in the US, early overseas reception, and expansion of the high-dose injectable were behind the upward revision to the full-year adjusted revenue and operating profit outlook. The numbers reinforce the same message. Adjusted Q2 revenue and operating profit both posted near double-digit growth at constant exchange rates, and the lower bound of full-year guidance was lifted materially.

That said, the market appears to be looking at the structure that remains after the upgrade, rather than the upgrade itself. While the company identifies growth drivers in oral, overseas launches, and GLP-1 volume, it still guided full-year adjusted growth to flat to a slight contraction. The fact that one-off charges and prior-year base effects pushed down IFRS profit is a point that less experienced investors may misread if they only glance at the headline scorecard, making it important to distinguish between adjusted and reported metrics.

Market Reaction and Forward Watchpoints

After-hours trading produced only a modest gain. The beat on adjusted results and the guidance upgrade are positives, but the decline in IFRS net profit, the large impairment charge, and the fact that the full-year growth guidance still includes a negative range appear to have offset the optimism. With much of the Wegovy oral momentum already priced in, the natural read is that the market has moved into a phase that weighs "the size of further upgrades" and "the quality of earnings."

Watch whether second-half US Wegovy oral prescription persistence and realized pricing across insurance and out-of-pocket channels determine revenue quality.

Track how quickly Wegovy oral and high-dose pen launches in Europe, the UK, and other overseas markets translate into actual sales.

Check whether the adjusted operating margin from Q3 onward moves closer to the top end of guidance (around 0%) without additional impairments or one-off costs.